Bloomberg Businessweek USA – July 2026
Summary
"Eli Lilly's Next Shot" — Bloomberg Businessweek's July 2026 issue puts CEO Dave Ricks on the cover, photographed through a red gel to nod at Lilly's company colour, after the drugmaker built a GLP-1 franchise worth USD 1 trillion. The issue also covers SpaceX's record-breaking IPO, the black-market peptide economy, and a special section on reluctant bosses.
The cover feature at P34 examines what Lilly does next after conquering the obesity market with Zepbound and the oral GLP-1 Foundayo, introduced in April. The SpaceX IPO on June 12 closed at a USD 2.1 trillion market capitalisation — the largest in history. Max Chafkin's Remarks (P8) dismantles the filing's USD 28.5 trillion addressable-market claim. The Reluctant Boss section (P61-P74) covers the corner-office crisis, middle-manager layoffs, and CEO survey data. In Context covers El Nino, robot legs, Japan's used-luxury market, and a Guinness interview.
—————
Content Guide
▸ Cover Story / Features
P34 · Lilly Tackled the Obesity Epidemic. What's Next?
Madison Muller and Brad Stone report from Indianapolis on Dave Ricks' next moves after Zepbound and Foundayo (the oral GLP-1 launched in April). The piece covers pipeline candidates, pricing strategy and the manufacturing capacity race. Any pharma executive planning a GLP-1 market entry should study Lilly's supply-chain playbook.
P42 · Inside the Multibillion-Dollar Peptide Economy
Amanda Mull and Ashleigh Furlong report on the black market for GLP-1-like peptides. The Janoshik testing lab in Czechia has a useful neighbour: a waste management company that destroys tested samples. Compliance officers in pharma and supplement industries should read the enforcement gap analysis.
P52 · How One Town Is Contending With an ICE Facility
Fola Akinnibi and photographer Caroline Gutman (who flew a drone to capture the 1.3-million-square-foot warehouse) report from Tremont, Pennsylvania, a coal-region town adjusting to a federal immigration detention centre as its largest employer.
▸ Remarks
P8 · Strap Yourself Into Starship Elon
Max Chafkin (who has covered Musk for 19 years) dissects the June 12 SpaceX IPO. The filing claims a USD 28.5 trillion addressable market; last year's revenue was USD 18.7 billion and the loss was USD 4.9 billion. The USD 2.1 trillion valuation rests heavily on what analyst Tim Farrar calls "the unknown Musk factor." Chafkin notes the SEC filing mentions the risk of Musk's death or disability — and that planning for it "hasn't even begun."
▸ The Reluctant Boss
P61 · Why It's Suddenly Not So Easy to Fill the Corner Office
Board members describe longer searches, higher comp demands and more candidates withdrawing after reference checks.
P66 · Declaring Open Season on Middle Managers
Companies are cutting middle-management layers at a pace not seen since the 2008 financial crisis.
P72 · Woe Be the CEO, According to Our Survey
Original survey data on CEO sentiment, burnout rates and how many would take the job again.
P74 · Rooting Out Bad Bosses With New Compliance Tools
Software platforms that track manager behaviour are being adopted by HR departments. The article flags the privacy and morale risks.
▸ In Context / In View
P11 · Economies Are Struggling. El Nino Won't Help
The compounding effect of climate shocks on already fragile national budgets.
P15 · The Booming Market for Japan's Used Luxury Goods
Depreciating yen and shifting consumer tastes are flooding the market with pre-owned Chanel, Rolex and Hermes.
P18 · A Walk With: Guinness's Grainne Wafer
The global head of the iconic Irish stout discusses brand stewardship and the non-alcoholic stout market.
P24 · The Scoop on Ice Cream Inflation
Dairy costs, packaging and logistics are pushing premium ice cream prices past USD 10 per pint.
P26 · With a US Retreat, China Exerts More Soft Power
The diplomatic vacuum left by the Trump administration is being filled by Chinese investment and cultural exports.
▸ Pursuits
P78 · VIP to Nosebleed: The World Cup's Best and Worst Seats
A stadium-by-stadium guide to the 2026 World Cup venue experience.
P81 · High-End Golf's Quiet Quest for Sandy Soil
Why the best new courses are being built on sand — and why that matters for land costs.
P84 · What to Read, Watch and Ponder in July
Curated picks across books, film and streaming.
—————
Editor's Take
The SpaceX Remarks piece by Max Chafkin is the best single article in this issue — it is funny, sceptical and numerically rigorous in a way that most IPO coverage is not. The Lilly cover story is solid but feels like a status report rather than a revelation; the more interesting read is the peptide black-market piece. The Reluctant Boss section is uneven: the CEO survey has genuine data value, but the "bad boss compliance tools" article reads like native advertising for an HR software category that barely exists. Best for pharma investors, IPO analysts and anyone who wants to understand how Musk's USD 2.1 trillion IPO filing was constructed.
Strengths
• Chafkin's SpaceX IPO analysis is the sharpest business writing in this issue
• Peptide black-market investigation is genuinely original
• Reluctant Boss CEO survey has useful sentiment data
Weaknesses
• Lilly cover story lacks the investigative edge of the peptide piece
• Compliance-tools article reads as an advertorial
Verdict: Recommended — Buy for the SpaceX Remarks piece and the peptide investigation.
